Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

wance was made after the Company determined that it was more likely than not that these deferred tax assets would be realized.  Due to the release of the valuation allowance in 2012, starting in 2013, the Company has recorded income taxes on GAAP income using an estimated effective tax rate. Non-GAAP net income excludes non-cash income tax expense.  The Company does not currently pay, or expect to pay in the near future, significant cash income taxes. 

Non-GAAP and GAAP Net Income: The Company reported non-GAAP net income of $201 million, or $2.07 per basic share and $1.78 per diluted share, in the first quarter of 2013, compared to non-GAAP net income of $40 million, or $0.43 per basic share and $0.37 per diluted share, in the first quarter of 2012.  Non-GAAP net income excludes non-cash share-based compensation expense, non-cash interest expense related to the convertible senior notes, and non-cash income tax expense. 

The Company reported GAAP net income of $99 million, or $1.02 per basic share and $0.90 per diluted share, in the first quarter of 2013, compared to GAAP net income of $12 million, or $0.12 per basic share and $0.11 per diluted share, in the first quarter of 2012. 

Cash Position: At March 31, 2013, cash and marketable securities totaled $663 million (including $8 million of restricted cash and marketable securities), compared to $588 million (including $8 million of restricted cash and marketable securities) at December 31, 2012.  In addition, accounts receivable related to sales of EYLEA totaled $702 million at March 31, 2013, compared to $592 million at December 31, 2012.

Use of Non-GAAP Financial Measures: The Company believes that the presentation of non-GAAP measures is useful to investors because it excludes (i) non-cash share-based compensation expense which fluctuates from period to period based on factors that are not within the Company's control, such as the Company's stock
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Regeneron Announces March 2012 Investor Conference Presentations
5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  Heidrick & Struggles (Nasdaq: ... , leadership consulting and culture shaping ... the firm to lead its global Healthcare and Life Sciences ... and Life Sciences, Mitchell will lead a team of more ... Europe and Asia ...
(Date:3/30/2015)... 2015 US-Australian drug discovery company, Novogen Ltd, ... Inc., and Yale University, on March 27 released pre-clinical ... presented as an oral presentation by Professor Gil ... the 62 nd Annual Scientific Meeting of the ... CA. In both in vitro ...
(Date:3/30/2015)... Md. , March 30, 2015    ... leader in synthetic biology, and Merck Serono, the ... Germany , today announced an exclusive strategic ... Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This ... develop innovative therapies that modulate the immune system,s ...
(Date:3/30/2015)... , March 30, 2015 ... novel biological drugs to treat cancer, viral infections ... Professor Sir John Bell , the Regius ... of the Office for the Strategic Coordination of ... immediate effect.      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ...
Breaking Biology Technology:Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5
... - Dr. Yong Shi of Stevens Institute of ... his project titled "MEMS Umbrella-Shaped Actuator with Active ... on scientific/technical merit for three years and will ... is to design, fabricate and test an umbrella-shaped ...
... Anesiva,Inc. (Nasdaq: ANSV ) today announced ... senior vice president and chief medical officer. Dr.,Houghton ... "Bill brings to Anesiva deep commercial and product ... background in,anesthesiology," said Mr. Kranda. "He fills a ...
... RapidArc Used to Deliver Stereotactic Radiosurgery for Brain ... Two leading cancer,centers have carried out groundbreaking radiosurgery ... technology from,Varian Medical Systems (NYSE: VAR ). ... University Medical Center in Amsterdam, Netherlands were,each able ...
Cached Biology Technology:Dr. Yong Shi awarded NSF grant 2Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer 2Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 4
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
(Date:3/16/2015)... , March 16, 2015 ... GmbH will present groundbreaking innovations in biometric identification ... Germany .      (Photo: ... biometric innovation is well at the forefront: the ... e-gate made in Germany . ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... University] By tuning gold nanoparticles to just the right ... selectively converts carbon dioxide (CO 2 ) to carbon monoxide ... make alternative fuels and commodity chemicals. "Our study shows ... into useful forms of carbon," said Shouheng Sun, professor ...
... as our bodies have skeletons, so do our cells. They,re ... go limp and fall down. And without our cytoskeletons, our ... would all become tiny spheres and stop working. Using ... system, Ram Dixit,s lab at Washington University in St. Louis ...
... in California,s Yolo Bypass provide,an all-you-can-eat bug buffet ... the sea. That,s according to a new report,detailing ... fish,in harvested rice fields earlier this year, resulting ... state,s rivers. The report, provided to the ...
Cached Biology News:Gold nanoparticles give an edge in recycling CO2 2Samurai sword protein makes strategic cuts in cell skeletons 2Samurai sword protein makes strategic cuts in cell skeletons 3Samurai sword protein makes strategic cuts in cell skeletons 4Samurai sword protein makes strategic cuts in cell skeletons 5For fish and rice to thrive in Yolo Bypass, 'just add water' 2For fish and rice to thrive in Yolo Bypass, 'just add water' 3
... Kit provides an extremely fast and ... intact protein complexes. Unlike other systems ... purification steps, this system takes advantage ... Column for fast protein purification under ...
Liquid. Phycoerythrin conjugate is in PBS, pH 7.4 containing 1% BSA and 0.1% sodium azide....
Request Info...
... Supercoiled DNA Ladder is suitable ... 2 to 16 kb by ... bands can be visualized by ... also be detected on Southern ...
Biology Products: